This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

Advanz won a temporary reprieve in September after the General Court of the European Union ordered a suspension of the EC's ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

The meeting was held November 15-19, 2024 in San Diego, California. The presentation entitled “Pharmacokinetics, Safety and Efficacy of the Novel Non-bile Acid FXR Agonist FXR314 in Patients with ...

New Xbox Series X games will start arriving thick and fast once over the next few months, with new exclusives launching on Microsoft's most powerful consoles. There's certainly a lot to look ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...